Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM). | Publicación